Phibro Animal Health (PAHC) Upgraded by Zacks Investment Research to Hold
Phibro Animal Health (NASDAQ:PAHC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Monday.
According to Zacks, “Phibro ended second-quarter fiscal 2018 on a mixed note, with bottom line exceeding the Zacks Consensus Estimate and revenues declining marginally on a year-over-year basis. Segment-wise, a persistent decline in Mineral Nutrition segment sales is likely to prove a drag. Customer consolidation can also adversely affect Phibro’s revenues. Moreover, headwinds such as unfavorable currency movement and tough competitive scenario continue to pose threats. Over the past three months, Phibro has been trading below the broader industry. However, on a positive note, Animal Health remained the key contributing business, delivering positive growth on a year-over-year basis. We are also encouraged by the expansion in the gross margin in the reported quarter.”
A number of other research firms also recently issued reports on PAHC. BidaskClub downgraded shares of Phibro Animal Health from a “sell” rating to a “strong sell” rating in a research note on Friday, December 29th. ValuEngine downgraded shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $42.00 price target on shares of Phibro Animal Health in a research note on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Phibro Animal Health currently has a consensus rating of “Hold” and an average price target of $38.25.
Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Monday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.01. The business had revenue of $193.40 million for the quarter, compared to the consensus estimate of $189.89 million. Phibro Animal Health had a net margin of 8.87% and a return on equity of 42.75%. The business’s revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.36 EPS. equities research analysts forecast that Phibro Animal Health will post 1.57 earnings per share for the current year.
Hedge funds have recently made changes to their positions in the stock. KBC Group NV acquired a new stake in Phibro Animal Health in the 2nd quarter valued at about $166,000. Victory Capital Management Inc. grew its stake in shares of Phibro Animal Health by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 5,380 shares of the company’s stock valued at $199,000 after buying an additional 807 shares in the last quarter. Capital Fund Management S.A. bought a new stake in shares of Phibro Animal Health in the 2nd quarter valued at approximately $210,000. Susquehanna International Group LLP bought a new stake in shares of Phibro Animal Health in the 2nd quarter valued at approximately $219,000. Finally, BNP Paribas Arbitrage SA grew its stake in shares of Phibro Animal Health by 55.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 5,933 shares of the company’s stock valued at $220,000 after buying an additional 2,123 shares in the last quarter. Hedge funds and other institutional investors own 48.42% of the company’s stock.
WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/08/phibro-animal-health-pahc-upgraded-by-zacks-investment-research-to-hold.html.
About Phibro Animal Health
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.